Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.60 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | KLK7 | P49862 | 4/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1403568 | 0.94 | PTGS1 (0.67) | PTGS1AKR1C3AKR1C2MEN1KMT2A | |
| SCHEMBL6886141 | 0.86 | PTGS1 (0.72) | PTGS1AKR1C3AKR1C2MEN1KMT2A | |
| SCHEMBL6884586 | 0.86 | PTGS1 (0.63) | PTGS1AKR1C3AKR1C2MAPTSMN1; SMN2 | |
| Methane SCHEMBL9655000 | 0.84 | PTGS1 (0.70) | PTGS1AKR1C3AKR1C2MEN1KMT2A | |
| Methane SCHEMBL9653230 | 0.84 | PTGS1 (0.55) | PTGS1AKR1C3AKR1C2MEN1KMT2A | |
| SCHEMBL6886448 | 0.83 | PTGS1 (0.53) | PTGS1AKR1C3AKR1C2MEN1KMT2A | |
| SCHEMBL27767912 | 0.83 | PTGS1 (0.63) | PTGS1AKR1C3AKR1C2MEN1KMT2A | |
| SCHEMBL25968365 | 0.82 | PTGS1 (0.67) | PTGS1AKR1C3AKR1C2MEN1KMT2A | |
| SCHEMBL1448732 | 0.81 | PTGS1 (0.73) | PTGS1AKR1C3AKR1C2MEN1KMT2A | |
| SCHEMBL924496 | 0.80 | KMT2A (0.63) | MEN1KMT2ACYP3A4KLK7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730701-B2 | 6-METHOXY-2-NAPHTHYLACETIC ACID DERIVATIVE AS A PRODRUGS, USEFUL FOR TREATMENT OF INFLAMMATION IN HUMANS | NOBEX CORPORATION | 2004-05-04 | — | — | US | disclosed |
| US-6713510-B2 | AMIDE AND ESTER DERIVATIVES | NOBEX CORPORATION | 2004-03-30 | — | — | US | disclosed |
| US-6653348-B2 | Antiinflammatory agent for humans | NOBEX CORPORATION | 2003-11-25 | — | — | US | disclosed |
| US-6610739-B2 | Amide and ester derivatives | NOBEX CORPORATION | 2003-08-26 | — | — | US | disclosed |
| EP-1335718-A1 | 6-METHOXY-2-NAPHTHYLACETIC ACID PRODRUGS | Nobex Corporation (US) | 2003-08-20 | — | — | EP | disclosed |
| US-6552078-B2 | Antiinflammatory and antiarthritic agents; rheumatic diseases; side effect reduction; ulcer and allergy resistance; non-irritating; easily hydrolyzed and solubilized; bioavailability | BIOCON LIMITED (IN) | 2003-04-22 | — | — | US | disclosed |
| US-20030027860-A1 | 6-Methoxy-2-naphthylacetic acid prodrugs | BIOCON LIMITED (IN) | 2003-02-06 | — | — | US | disclosed |
| US-20030027861-A1 | 6-Methoxy-2-naphthylacetic acid prodrugs | BIOCON LIMITED (IN) | 2003-02-06 | — | — | US | disclosed |
| US-20030013762-A1 | 6-methoxy-2-naphthylacetic acid prodrugs | BIOCON LIMITED (IN) | 2003-01-16 | — | — | US | disclosed |
| US-6436990-B1 | ANTIINFLAMMATORY, RHEUMATIC AND ANTIARTHRITIC AGENTS, HAVING IMPROVED TRANSFORMATION; SIDE EFFECT REDUCTION | NOBEX CORPORATION | 2002-08-20 | — | — | US | disclosed |
| EP-1223926-A2 | 6-METHOXY-2-NAPHTHYLACETIC ACID PRODRUGS COMPOSITIONS FOR TREATING INFLAMMATION | Nobex Corporation (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2002034260-A1 | 6-METHOXY-2-NAPHTHYLACETIC ACID PRODRUGS | NOBEX CORPORATION (US) | 2002-05-02 | — | — | WO | disclosed |
| US-20020028845-A1 | 6-methoxy-2-naphthylacetic acid prodrugs | BIOCON LIMITED (IN) | 2002-03-07 | — | — | US | disclosed |
| WO-2001030334-A2 | 6-METHOXY-2-NAPHTHYLACETIC ACID PRODRUGS COMPOSITIONS FOR TREATING INFLAMMATION | NOBEX CORPORATION (US) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013762-A1 | 6-methoxy-2-naphthylacetic acid prodrugs | IL6, CYP2A6, TLR6 | PTGS1 588/4885AKR1C3 80/4885AKR1C2 213/4885 |
| US-20020028845-A1 | 6-methoxy-2-naphthylacetic acid prodrugs | IL6, CYP2A6, TLR6 | PTGS1 648/4885AKR1C3 64/4885AKR1C2 179/4885 |
| US-20030027861-A1 | 6-Methoxy-2-naphthylacetic acid prodrugs | IL6, CYP2A6, TLR6 | PTGS1 588/4885AKR1C3 80/4885AKR1C2 213/4885 |
| US-20030027860-A1 | 6-Methoxy-2-naphthylacetic acid prodrugs | IL6, CYP2A6, TLR6 | PTGS1 588/4885AKR1C3 80/4885AKR1C2 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.